Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL152867 | 0.83 | SLC5A2 (0.46) | SLC5A2SLC5A1 | |
| SCHEMBL462745 | 0.79 | SLC5A2 (0.47) | SLC5A2MEN1KMT2AMAPTESR1 | |
| SCHEMBL469674 | 0.79 | SLC5A2 (0.49) | SLC5A2MEN1KMT2AALOX5HPGD | |
| SCHEMBL469637 | 0.78 | SLC5A2 (0.35) | SLC5A2MEN1KMT2AMAPT | |
| SCHEMBL462174 | 0.75 | SLC5A2 (0.52) | SLC5A2MAPTSLC5A1 | |
| SCHEMBL462685 | 0.74 | SLC5A2 (0.53) | SLC5A2KMT2AMAPTHSD17B10 | |
| SCHEMBL462800 | 0.72 | SLC5A2 (0.37) | SLC5A2 | |
| SCHEMBL454920 | 0.71 | — | — | |
| SCHEMBL30117334 | 0.70 | MEN1 (0.54) | MEN1KMT2AMAPTESR1ESR2 | |
| SCHEMBL29816996 | 0.70 | MEN1 (0.46) | SLC5A2MEN1KMT2AMAPTESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006187-B2 | Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2015-04-14 | — | — | US | disclosed |
| US-9006187-B2 | Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2015-04-14 | — | — | US | disclosed |
| US-9006187-B2 | Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2015-04-14 | — | — | US | disclosed |
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2013-07-04 | — | — | US | disclosed |
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2013-07-04 | — | — | US | disclosed |
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2013-07-04 | — | — | US | disclosed |
| WO-2012033390-A2 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012033390-A2 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885MEN1 4525/4885KMT2A 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.